Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3589
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Sodium Phosphate P 32 (Solution)
|
| dailymed-instance:dosage |
The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Oral administration of high-specific-activity Sodium Phosphate P 32 in the fasting state may equal intravenous administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Waterproof gloves should be used during the entire handling and administration procedure. Maintain adequate shielding during the life of the product and use a sterile, shielded syringe for withdrawing and injecting the drug. For polycythemia vera, intravenous dosages from 37 to 296 megabecquerels (1 to 8 millicuries) are given depending upon the stage of disease and size of the patient. Repeat doses must be adjusted to individual needs. For chronic leukemia, the individual dose is 222 to 555 megabecquerels (6 to 15 millicuries), usually administered with concomitant hormone manipulation.
|
| dailymed-instance:descripti... |
Sterile, non-pyrogenic Sodium Phosphate P 32 is available for therapeutic application as an intravenous solution dosage form with a concentration of 24.8 megabecquerels (0.67 millicurie) per milliliter. The intravenous solution contains 1.6 milligrams per milliliter of sodium acetate as a buffer, 0.9% sodium chloride forisotonicity and may contain sodium hydroxide or hydrochloric acid for pH adjustment. The pH of the solution is between 5.0 and 6.0.
|
| dailymed-instance:clinicalP... |
Phosphorus is necessary to metabolic and proliferative activity of cells. Radioactive phosphorus concentrates to a very high degree in rapidly proliferating tissue.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Sodium Phosphate P 32 should not be used as a part of sequential treatment with a chemotherapeutic agent. In polycythemia vera, Sodium Phosphate P 32 should not be administered when the leukocyte count is below 5,000/cu mm, or a platelet count is below 150,000/cu mm. In chronic myelocytic leukemia, Sodium Phosphate P 32 should not be administered when the leukocyte count is below 20,000/cu mm. For treatment of bone metastases it is usually not administered when the leukocyte count is below 5,000/cu mm, and platelet count is below 100,000/cu mm.
|
| dailymed-instance:supply |
Catalog Number 461 Sodium Phosphate P 32 is supplied as a sterile, non-pyrogenic solution in single dose vials containing 185 megabequerels (5 millicuries) of phosphorus P 32. Each milliliter contains 24.8 megabecquerels (0.67 millicuries) sodium phosphate P 32 at the time of calibration, 1.6 milligrams sodium acetate and 9 milligrams sodium chloride. The solution may contain sodium hydroxide or hydrochloric acid for pH adjustment.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
Sodium Phosphate, P-32
|
| dailymed-instance:fullName |
Sodium Phosphate P 32 (Solution)
|
| dailymed-instance:adverseRe... |
None known.
|
| dailymed-instance:warning |
This radiopharmaceutical should administered for intracavitary use. Overdose of Sodium Phosphate P 32 may produce serious effects on the hemopoietic system. The blood and bone marrow should be carefully monitored at regular intervals. Sodium Phosphate P 32 ordinarily does not localize in retinoblastomas.
|
| dailymed-instance:indicatio... |
The principal use of Sodium Phosphate P 32 is for the treatment of polycythemia vera, and it is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. Sodium Phosphate P 32 is also used in palliative treatment of selected patients with multiple areas of skeletal metastases.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Sodium Phosphate P 32
|